Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 in patients with symptomatic heart failure with preserved ejection fraction with left ventricular ejection fraction greater than or equal to60%. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of with symptomatic HFpEF patients with hypercontractility and ventricular hypertrophy.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics CEO not looking to be bought, but would listen, STAT says
- Cytokinetics provided milestones expected in 2025
- Cytokinetics announces EMA has validated MAA for aficamten
- Sanofi to acquire rights to develop, commercialize aficamten from Corxel
- Cytokinetics price target raised to $82 from $80 at RBC Capital